文献速递泌尿男性生殖肿瘤

贝组替凡对比依维莫司治疗晚期肾细胞癌的健康相关生活质量(LITESPARK-005):随机开放标签3期试验的患者报告结局

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2025-03-17

LITESPARK-005研究在147家医院和癌症中心入组746例晚期透明细胞肾细胞癌患者,随机接受贝组替凡120 mg每日一次或依维莫司10 mg每日一次。从基线至第17周,贝组替凡组FKSI-DRS评分和QLQ-C30总体健康状况-生活质量评分较依维莫司组改善,组间最小二乘均值差异分别为1.5(95%CI 0.7-2.2)和6.4(95%CI 3.2-9.6)。

要点

  • 贝组替凡组第17周FKSI-DRS评分变化较依维莫司组改善,组间差异1.5(95%CI 0.7-2.2)。
  • 贝组替凡组QLQ-C30总体健康状况-生活质量评分较依维莫司组改善,组间差异6.4(95%CI 3.2-9.6)。
  • 至恶化时间在体力功能和角色功能方面两组相似,风险比分别为0.93和0.88。

核心结论

  • 贝组替凡治疗晚期肾细胞癌与依维莫司相比,与疾病特异性症状和生活质量改善相关。
  • 结合LITESPARK-005的疗效和安全性数据,贝组替凡可能在不损害该情境下患者生活质量的情况下提供临床获益。

研究设计与样本

  • LITESPARK-005为开放标签、多中心、随机、活性对照3期试验,在六个区域147家医院和癌症中心开展。
  • 入组标准:18岁及以上晚期透明细胞肾细胞癌,卡氏功能状态评分70%或以上,具有可测量病灶,抗PD-1或抗PD-L1免疫治疗和VEGF酪氨酸激酶抑制剂治疗期间或之后疾病进展,既往系统治疗线数不超过三线。
  • 随机分配:746例参与者按1:1随机接受贝组替凡120 mg口服每日一次(n=374)或依维莫司10 mg口服每日一次(n=372)。
  • PRO分析人群:贝组替凡组366例,依维莫司组354例,为接受至少一剂研究治疗并完成至少一次PRO评估的参与者。

主要发现

  • 从基线至第17周FKSI-DRS评分变化:组间最小二乘均值差异1.5(95%CI 0.7-2.2),提示贝组替凡组稳定而依维莫司组恶化。
  • 从基线至第17周QLQ-C30总体健康状况-生活质量评分变化:组间最小二乘均值差异6.4(95%CI 3.2-9.6),提示贝组替凡组稳定而依维莫司组恶化。
  • 从基线至第17周QLQ-C30体力功能子量表评分变化组间最小二乘均值差异2.5(95%CI -0.6-5.5),角色功能子量表评分差异4.2(95%CI 0.1-8.4),两组相似。
  • EORTC体力功能至恶化时间:贝组替凡组中位19.3个月(95%CI 11.1-未达到)vs 依维莫司组13.8个月(95%CI 10.6-未达到),风险比0.93(95%CI 0.72-1.20)。
  • EORTC角色功能至恶化时间:贝组替凡组中位12.0个月(95%CI 9.2-未达到)vs 依维莫司组10.2个月(95%CI 4.7-14.4),风险比0.88(95%CI 0.69-1.11)。

关键数值与推荐

  • FKSI-DRS和QLQ-C30完成率:基线时各组均高于94%,第17周时各组均高于55%。
  • 从随机分组至数据库截止日期(2023年6月13日)的中位时间为25.7个月(IQR 21.7-30.4)。

临床怎么用

  • 原文结论认为贝组替凡可能在不损害该情境下患者生活质量的情况下提供临床获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The first-in-class hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan is approved for patients with advanced renal cell carcinoma previously treated with immune checkpoint and anti-angiogenic therapy based on results of the phase 3 LITESPARK-005 trial. We present patient-reported outcomes (PROs) from LITESPARK-005. METHODS: LITESPARK-005 was an open-label, multicentre, randomised, active-controlled phase 3 trial conducted at 147 hospitals and cancer centres in six regions. Eligible participants were 18 years or older with advanced clear cell renal cell carcinoma, had a Karnofsky Performance Status score of 70% or higher, had measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, had disease progression on or after treatment with anti-PD-1 or anti-PD-L1 immunotherapy and a VEGF tyrosine kinase inhibitor (in sequence or in combination), and had received no more than three previous systemic lines of therapy. Eligible participants were randomly assigned (1:1) centrally using interactive voice-response and web-response systems to receive either belzutifan 120 mg orally once daily or everolimus 10 mg orally once daily. Randomisation was stratified by International Metastatic Renal Cell Carcinoma Database Consortium prognostic score and number of previous VEGF-targeted or VEGF receptor-targeted therapies. The dual primary outcomes were progression-free survival and overall survival, results of which have been reported previously. In this study, prespecified secondary patient-reported outcomes (PROs) from LITESPARK-005 were assessed using the Functional Assessment of Cancer Therapy-Kidney Cancer Symptom Index: Disease Related Symptoms (FKSI-DRS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The PRO analysis population included all participants who received at least one dose of study therapy and completed at least one PRO assessment. Least-squares mean change from baseline in PROs at week 17 was assessed using a constrained longitudinal data analysis model. Time to deterioration in physical functioning (prespecified) and role functioning (post hoc), as assessed by the EORTC QLQ-C30, were also evaluated in the PRO analysis population. This trial is ongoing, closed to recruitment, and registered with ClinicalTrials.gov, NCT04195750. FINDINGS: Between March 10, 2020, and Jan 19, 2022, 996 participants were screened for eligibility and 746 participants were randomly assigned to belzutifan (n=374) or everolimus (n=372). The PRO full analysis set population included 366 participants in the belzutifan group and 354 in the everolimus group. Median time from randomisation to the database cutoff date (June 13, 2023) was 25·7 months (IQR 21·7-30·4). Completion rates for FKSI-DRS and QLQ-C30 were higher than 94% at baseline and higher than 55% at week 17 in each group. Change from baseline to week 17 in FKSI-DRS score (difference in least-squares mean between groups 1·5 [95% CI 0·7 to 2·2]) and QLQ-C30 global health status-quality of life (QOL) score (6·4 [3·2 to 9·6]) suggested stability with belzutifan versus worsening with everolimus. Change from baseline to week 17 was similar between groups for QLQ-C30 physical functioning (difference in least-squares mean 2·5 [95% CI -0·6 to 5·5]) and QLQ-C30 role functioning (4·2 [0·1 to 8·4]) subscale scores. Time to deterioration was similar between the belzutifan and everolimus groups for EORTC physical functioning (median 19·3 months [95% CI 11·1 to not reached] in the belzutifan group vs 13·8 months [10·6 to not reached] in the everolimus group; hazard ratio 0·93 [95% CI 0·72 to 1·20]) and role functioning (median 12·0 months [9·2 to not reached] vs 10·2 months [4·7 to 14·4]; 0·88 [0·69 to 1·11]). INTERPRETATION: Belzutifan for advanced renal cell carcinoma was associated with improved disease-specific symptoms and QOL compared with everolimus. Taken together with the efficacy and safety data from LITESPARK-005, belzutifan could offer a clinical benefit without compromising the QOL of patients in this setting. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Powles T, Choueiri TK, Albiges L, et al. Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2025. PMID: 40112850. doi:10.1016/S1470-2045(25)00032-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。